Pathophysiology of Primary Aldosteronism
Primary aldosteronism is a disorder where the adrenal glands produce excessive aldosterone that is inappropriately high for sodium status, operates autonomously from its normal regulators (angiotensin II and potassium), and cannot be suppressed with sodium loading. 1, 2, 3
The Secreted Hormone and Its Normal Regulation
Aldosterone is the primary hormone secreted in excess in this condition. Under normal physiology, aldosterone production from the zona glomerulosa of the adrenal cortex is tightly regulated by three main factors 4, 5:
- Angiotensin II (primary regulator)
- Extracellular potassium (primary regulator)
- ACTH (adrenocorticotropic hormone) (acute regulator)
- Serotonin (minor acute regulator)
In primary aldosteronism, this regulatory system becomes disrupted—aldosterone secretion becomes relatively autonomous and renin-independent 1, 2, 3.
Pathophysiological Mechanisms
Molecular and Cellular Basis
The excessive aldosterone production results from 4, 6:
- Somatic or germline mutations affecting ion channels or intracellular signaling pathways
- Dysregulated calcium flux in adrenal cells
- Overexpression of melanocorticoid type 2 receptor (MC2R), making cells abnormally responsive to ACTH 5
- Aberrant expression of ectopic hormone receptors that respond to inappropriate ligands
These molecular abnormalities lead to morphological changes in the adrenal cortex, including aldosterone-producing cell clusters (APCCs), micronodules, and aldosterone-producing adenomas (APAs) 4.
Structural Causes
The anatomical distribution is approximately 1, 2, 3:
- Two-thirds (66%): Bilateral adrenal hyperplasia (idiopathic hyperaldosteronism)
- One-third (33%): Unilateral aldosterone production
- Most commonly: aldosterone-producing adenoma
- Less commonly: unilateral adrenal hyperplasia
- Rarely: adrenal carcinoma
Note the shift from older guidelines: The 2018 ACC/AHA guidelines stated 50/50 distribution 1, 7, but the most recent 2025 guidelines reflect updated epidemiology showing bilateral disease predominates 2, 3.
Downstream Physiological Effects
The excessive aldosterone acts through the mineralocorticoid receptor (MR) to cause 1, 2, 3:
Renal Effects
- Sodium retention → intravascular volume expansion
- Increased potassium excretion → hypokalemia (though absent in majority of cases)
- Suppressed plasma renin activity (due to volume expansion)
Cardiovascular and Organ Damage
The aldosterone excess causes direct tissue toxicity independent of blood pressure elevation 2, 3:
- 2.8-fold increased risk of stroke
- 2.0-fold increased risk of heart failure
- 4.0-fold increased risk of atrial fibrillation
- 1.7-fold increased risk of coronary artery disease
- Progressive kidney damage
Important Clinical Pitfall
Hypokalemia is absent in the majority of PA cases and has low negative predictive value 1, 2, 3. This is a critical point—clinicians cannot rely on the presence of hypokalemia to screen for or exclude primary aldosteronism. The condition should be suspected based on hypertension patterns (especially resistant hypertension) rather than electrolyte abnormalities alone.
The ACTH Connection
An important nuance in PA pathophysiology is the role of ACTH 5:
- Patients with PA show exaggerated aldosterone response to ACTH compared to normal individuals
- Diurnal variation in aldosterone follows ACTH patterns (morning peaks)
- Dexamethasone suppresses aldosterone in PA, confirming ACTH's role
- This explains why some aldosterone-producing adenomas show variable secretion patterns
In the rare familial form (glucocorticoid-remediable aldosteronism), a chimeric gene places aldosterone synthase under ACTH control, making aldosterone production completely ACTH-dependent 5.
Clinical Significance
This pathophysiology explains why PA causes disproportionate cardiovascular damage compared to essential hypertension at similar blood pressure levels—the direct mineralocorticoid receptor activation in multiple tissues (heart, vessels, kidneys, brain) causes damage beyond hemodynamic effects 2, 3, 4.